This is a working overview of synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-29 and is reviewed periodically as new material appears.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Hypersensitivity to CPA or any of the other components of the medication Pregnancy, lactation, and breastfeeding Puberty (except if being used to treat precocious puberty or delay puberty) Liver diseases and liver dysfunction Chronic kidney disease Dubin–Johnson syndrome and Rotor syndrome History of jaundice or persistent pruritus during pregnancy History of herpes during pregnancy Previous or existing liver tumors (only if not due to metastases from prostate cancer) Previous or existing meningioma, hyperprolactinemia, or prolactinoma Wasting syndromes (except in inoperable prostate cancer) Severe depression Previous or existing thromboembolic processes, as well as stroke and myocardial infarction Severe diabetes with vascular changes Sickle-cell anemia When CPA is used in combination with an estrogen, contraindications for birth control pills should also be considered.
In the absence of a gut compartment, input can be made directly in the liver. However, in that case local metabolism in the gut may not be correctly described. The case of approximately continuous absorption (e.g. via drinking water) can be modeled by a zero-order absorption rate (here Ring in units of mass over time):
Erythrocruorin Found in many annelids, including earthworms, it is a giant free-floating blood protein containing many dozens—possibly hundreds—of iron- and heme-bearing protein subunits bound together into a single protein complex with a molecular mass greater than 3.5 million daltons. Leghemoglobin In leguminous plants, such as alfalfa or soybeans, the nitrogen fixing bacteria in the roots are protected from oxygen by this iron heme containing oxygen-binding protein. The specific enzyme protected is nitrogenase, which is unable to reduce nitrogen gas in the presence of free oxygen. Coboglobin A synthetic cobalt-based porphyrin. Coboprotein would appear colorless when oxygenated, but yellow when in veins.
The sale allows TGI Fridays to repay its $23.9 million bankruptcy loan, with about $8 million in cash left over. On January 29, 2025, it was announced TGI Fridays UK's flagship restaurant in Leicester Square, London, had closed down. On January 30, 2025, it was reported that 30 more locations had closed, which left the chain with only around 100 locations remaining in the US. On February 3, 2025, it was announced that 19 of TGI Fridays' corporate-owned restaurants had been sold to two separate franchisees: three to Sugarloaf Hospitality and 16 to Yadav Enterprises, and that TGI Fridays had rejected the leases for six more restaurants. On 31 October 2025, it was announced that Sugarloaf TGIF Management had acquired TGI Friday's 49 UK restaurants from Calveton UK and Breal Capital as part of an international consolidation of the brand under Ray Blanchette. Sugarloaf is establishing a UK-led management team for the restaurants. However, less than three months later, on 14 January 2026, TGI Fridays closed 16 restaurants and went into administration for the second time in a year.
== Historical uses == In 1959, the combination of phenoperidine and haloperidol was first used in Europe in anesthesia to induce a detached, pain free state called neuroleptic analgesia; the use of that mixture boomed in early 1960s but was overtaken by the combination of fentanyl and droperidol, which was widely used through the 1980s. These combination approaches were not adopted in the US.
Sources: en.wikipedia.org
People can also develop CJD because they carry a mutation of the gene that codes for the prion protein (PRNP), located on chromosome 202p12-pter. This occurs in only 10–15% of all CJD cases. In sporadic cases, the misfolding of the prion protein is a process that is hypothesized to occur as a result of the effects of aging on cellular machinery, explaining why the disease often appears later in life. An EU study determined that "87% of cases were sporadic, 8% genetic, 5% iatrogenic and less than 1% variant." Testing for CJD has historically been problematic, due to the nonspecific nature of early symptoms and difficulty in safely obtaining brain tissue for confirmation. The diagnosis may initially be suspected in a person with rapidly progressing dementia, particularly when it is also found with the characteristic medical signs and symptoms such as involuntary muscle jerking, difficulty with coordination/balance and walking, and visual disturbances. Further testing can support the diagnosis and may include:
=== Hydroxides === The oxides and hydroxides of neptunium are closely related to its ions. In general, Np hydroxides at various oxidation levels are less stable than the actinides before it on the periodic table such as thorium and uranium and more stable than those after it such as plutonium and americium. This phenomenon is because the stability of an ion increases as the ratio of atomic number to the radius of the ion increases. Thus actinides higher on the periodic table will more readily undergo hydrolysis. Neptunium(III) hydroxide is quite stable in acidic solutions and in environments that lack oxygen, but it will rapidly oxidize to the IV state in the presence of air. It is not soluble in water. Np(IV) hydroxides exist mainly as the electrically neutral Np(OH)4 and its mild solubility in water is not affected at all by the pH of the solution. This suggests that the other Np(IV) hydroxide, Np(OH)−5, does not have a significant presence. Because the Np(V) ion NpO+2 is very stable, it can only form a hydroxide in high acidity levels. When placed in a 0.1 M sodium perchlorate solution, it does not react significantly for a period of months, although a higher molar concentration of 3.0 M will result in it reacting to the solid hydroxide NpO2OH almost immediately. Np(VI) hydroxide is more reactive but it is still fairly stable in acidic solutions. It will form the compound NpO3·H2O in the presence of ozone under various carbon dioxide pressures. Np(VII) has not been well-studied and no neutral hydroxides have been reported. It probably exists mostly as [NpO4(OH)2]3−.
=== PPAR-gamma agonists === PPARγ (gamma) is the main target of the drug class of thiazolidinediones (TZDs), used in diabetes mellitus and other diseases that feature insulin resistance. It is also mildly activated by certain NSAIDs (such as ibuprofen) and indoles, as well as from a number of natural compounds. Known inhibitors include the experimental agent GW-9662. They are also used in treating hyperlipidaemia in atherosclerosis. Here they act by increasing the expression of ABCA1, which transports extra-hepatic cholesterol into HDL. Increased uptake and excretion from the liver therefore follows. Animal studies have shown their possible role in amelioration of pulmonary inflammation, especially in asthma.
== Obesity == Obesity affects bone mineral density (BMD) and fracture risk. While increased weight may enhance BMD due to mechanical loading, it can also elevate fracture risk at specific skeletal sites. Studies suggest that obesity impacts bone quality, potentially increasing fragility. Magnesium is essential for bone health, contributing to bone formation and maintenance. Lower magnesium intake has been linked to reduced BMD, while higher intake may help protect against fractures, particularly in postmenopausal women. While obesity may increase BMD, body fat distribution and metabolic factors can negatively affect bone quality, potentially raising fracture risk.
Sources: en.wikipedia.org
== Notable people == Túpac Amaru II, revolutionary Angélica Mendoza de Ascarza, Peruvian human rights activist Kimberly Barzola, American community organizer and artist Benjamin Bratt, American actor Manco Cápac, Sapa Inca Luzmila Carpio, Bolivian musician Andrónico Rodríguez, Bolivian trade unionist and politician Martín Chambi, Peruvian photographer Renata Flores Rivera, Peruvian musician Oswaldo Guayasamín, Ecuadorian painter Ollanta Humala, former president of Peru Antauro Humala, Peruvian ethnocacerist Josh Keaton, American actor Q'orianka Kilcher, American actress Nancy Iza Moreno, Kichwa leader Leonidas Iza, Ecuadorian activist and Indigenous leader Delfín Quishpe, Ecuadorian musician and politician Tarcila Rivera Zea, Peruvian activist Izkia Siches, Chilean physician and politician Magaly Solier, Peruvian actress and musician Diego Quispe Tito, painter Francisco Tito Yupanqui, sculptor Alejandro Toledo, former president of Peru Edison Flores, Peruvian footballer Renato Tapia, Peruvian footballer Tania Pariona Tarqui, Peruvian politician
== Role in cancer == IRS-1, as a signalling adapter protein, is able to integrate different signalling cascades, which indicates its possible role in cancer progression. IRS-1 protein is known to be involved in various types of cancer, including colorectal, lung, prostate and breast cancer. IRS-1 integrates signalling from insulin receptor (InsR), insulin-like growth factor-1 receptor (IGF1R) and many other cytokine receptors and is elevated in β-catenin induced cells. Some evidence shows that TCF/LEF-β-catenin complexes directly regulate IRS-1. IRS-1 is required for maintenance of neoplasmic phenotype in adenomatous polyposis coli (APC) - mutated cells, it is also needed for transformation in ectopically expressing oncogenic β-catenin cells. IRS-1 dominant-negative mutant functions as tumor suppressor, whereas ectopic IRS-1 stimulates oncogenic transformation. IRS-1 is upregulated in colorectal cancers (CRC) with elevated levels of β-catenin, c-MYC, InsRβ and IGF1R. IRS-1 promotes CRC metastasis to the liver. Decreased apoptosis of crypt stem cells is associated with colon cancer risk. Reduced expression of IRS-1 in Apc (min/+) mutated mice shows increased irradiation-induced apoptosis in crypt. Deficiency in IRS-1 - partial (+/-) or absolute (-/-) - in Apc (min/+) mice demonstrates reduced amount of tumors comparing to IRS-1 (+/+)/ Apc (min/+) mice. In lung adenocarcinoma cell line A549 overexpression of IRS-1 leads to reduced growth. Tumor infiltrating neutrophils have recently been thought to adjust tumor growth and invasiveness.
=== Membrane transport === Contrary to common belief, thyroid hormones cannot traverse cell membranes in a passive manner like other lipophilic substances. The iodine in o-position makes the phenolic OH-group more acidic, resulting in a negative charge at physiological pH. However, at least 10 different active, energy-dependent and genetically regulated iodothyronine transporters have been identified in humans. They guarantee that intracellular levels of thyroid hormones are higher than in blood plasma or interstitial fluids.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.